The genomic landscape of teenage and young adult T‐cell acute lymphoblastic leukemia

Treatment on risk adapted intensive pediatric protocols has improved outcome for teenagers and young adults (TYA) with T‐cell acute lymphoblastic leukemia (T‐ALL). Understanding the biology of disease in this age group and the genetic basis of relapse is a key goal as patients with relapsed/refractory disease have poor outcomes with conventional chemotherapy and novel molecular targets are required. This study examines the question of whether TYA T‐ALL has a specific biological‐molecular profile distinct from pediatric or adult T‐ALL.

[1]  R. Hough,et al.  Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003 , 2018, British journal of haematology.

[2]  G. Basso,et al.  Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. , 2017, Blood.

[3]  M. Stevens,et al.  Are survival and mortality rates associated with recruitment to clinical trials in teenage and young adult patients with acute lymphoblastic leukaemia? A retrospective observational analysis in England , 2017, BMJ Open.

[4]  Cheng Cheng,et al.  THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA , 2017, Nature Genetics.

[5]  Andrew P. Stubbs,et al.  IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study , 2016, PLoS medicine.

[6]  Ryan D. Morin,et al.  Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas , 2015, Clinical Cancer Research.

[7]  V. Beneš,et al.  Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation , 2015, Haematologica.

[8]  J. Soulier,et al.  Targeted sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in T-cell acute lymphoblastic leukemia , 2015, Haematologica.

[9]  X. Chen,et al.  Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival , 2015, Annals of Hematology.

[10]  D. Linch,et al.  Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial , 2015, Leukemia.

[11]  J. Soulier,et al.  Distinctive genotypes in infants with T‐cell acute lymphoblastic leukaemia , 2015, British journal of haematology.

[12]  B. Johansson,et al.  Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A , 2015, Journal of Hematology & Oncology.

[13]  B. Johansson,et al.  Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia , 2015, Haematologica.

[14]  R. Wade,et al.  Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial , 2014 .

[15]  Na Li,et al.  Cyclin C is a haploinsufficient tumour suppressor , 2014, Nature Cell Biology.

[16]  R. Wade,et al.  Outcome for children and young people with Early T‐cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003 , 2014, British journal of haematology.

[17]  J. Cayuela,et al.  Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. , 2014, Blood.

[18]  Andrea Califano,et al.  Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. , 2013, Cancer cell.

[19]  Valeria Nofrini,et al.  Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. , 2013, Leukemia research.

[20]  T. Graeber,et al.  BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint , 2013, Nature Medicine.

[21]  M. Muckenthaler,et al.  NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia , 2013, Haematologica.

[22]  A. Kohlmann,et al.  The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL , 2013, Genes, chromosomes & cancer.

[23]  A. Ferrando,et al.  Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL , 2013, Nature Medicine.

[24]  R. Schuit,et al.  An intronic polymorphic deletion in the PTEN gene: implications for molecular diagnostic testing , 2013, British Journal of Cancer.

[25]  A. Ferrando,et al.  Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. , 2012, Blood.

[26]  K. Shannon,et al.  Targeting oncogenic Ras signaling in hematologic malignancies. , 2012, Blood.

[27]  A. Ferrando,et al.  The molecular basis of T cell acute lymphoblastic leukemia. , 2012, The Journal of clinical investigation.

[28]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[29]  M. Esteller,et al.  EPHA7, a new target gene for 6q deletion in T-cell lymphoblastic lymphomas. , 2012, Carcinogenesis.

[30]  A. Ferrando,et al.  ETV6 mutations in early immature human T cell leukemias , 2011, The Journal of experimental medicine.

[31]  L. Shaffer,et al.  Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T-cell acute lymphoblastic leukemia , 2011, Leukemia.

[32]  M. Greaves,et al.  Occurrence of identical NOTCH1 mutation in non-twinned sisters with T-cell acute lymphoblastic leukemia , 2011, Leukemia.

[33]  Kenneth H. Buetow,et al.  CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.

[34]  J. Meijerink.  Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. , 2010, Best practice & research. Clinical haematology.

[35]  M. Loh,et al.  Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Donna Neuberg,et al.  Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. , 2010, Blood.

[37]  A. Ferrando,et al.  T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). , 2009, Blood.

[38]  L. Chin,et al.  High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. , 2009, Blood.

[39]  James R. Downing,et al.  Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia , 2008, Science.

[40]  R. Pieters,et al.  Molecular‐genetic insights in paediatric T‐cell acute lymphoblastic leukaemia , 2008, British journal of haematology.

[41]  A. Hall,et al.  Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. , 2008, Cancer research.

[42]  E. Clappier,et al.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia , 2008, The Journal of experimental medicine.

[43]  Christopher B. Miller,et al.  Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia , 2007, Nature.

[44]  Cheng Cheng,et al.  Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. , 2006, Blood.

[45]  E. Macintyre,et al.  Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. , 2004, Blood.

[46]  R. Berger,et al.  Isochromosome 7q and trisomy 8 are consistent primary, non-random chromosomal abnormalities associated with hepatosplenic T gamma/delta lymphoma. , 1996, Leukemia.

[47]  A. Moorman,et al.  Isochromosomes in acute lymphoblastic leukaemia: I(21q) is a significant finding , 1996, Genes, chromosomes & cancer.

[48]  F. Behm,et al.  Abnormalities of the long arm of chromosome 6 in childhood acute lymphoblastic leukemia. , 1990, Blood.

[49]  D C Linch,et al.  Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial , 2013, Leukemia.

[50]  R. Arceci.  The genetic basis of early T–cell precursor acute lymphoblastic leukaemia , 2012 .

[51]  J. Salk.  Clonal evolution in cancer , 2010 .

[52]  A. Hall,et al.  A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups. , 2009, Blood.

[53]  Andrew P. Stubbs,et al.  The recurrent SET-NUP 214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia , 2008 .

[54]  L. Foroni,et al.  A Fluorescence in Situ Hybridization Map of 6q Deletions in Acute Lymphocytic Leukemia: Identification and Analysis of a Candidate Tumor Suppressor Gene , 2004 .